Latest CanVECTOR News
 

Annual incidence of

2/1000

population per year

Cost of VTE: at least

$600m

CAD a year

VTE recurrence

5-10%

per year

Chronic thromboembolic pulmonary hypertension 

3-4%

after PE

Pulmonary Embolism
leads to the hospitalization
or death of over

30,000

Canadians every year

VTE leads to significant

long-term
costs

in the form of chronic complications of VTE

Post-thrombotic syndrome

20-40%

after DVT

Adverse effects and

burden of anticoagulant therapy

Upcoming Events

Evidence Pearls on VTE

Evidence Pearls on VTE RSS Feed
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 27, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 27, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 27, 2017
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 26, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 26, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 26, 2017
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 25, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 25, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 25, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 24, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 24, 2017
YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy).
Feb 24, 2017
Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Feb 24, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 23, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 23, 2017
YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy).
Feb 23, 2017
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Feb 22, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 22, 2017
YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy).
Feb 22, 2017
Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding.
Feb 21, 2017
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next

Twitter